Dr. Fenske on the Utility of Next-Generation BTK Inhibitors in MCL

Video

Timothy Fenske, MD, MS, discusses the utility of next-generation BTK inhibitors in mantle cell lymphoma.

Timothy Fenske, MD, MS, associate professor at the Medical College of Wisconsin, discusses the utility of next-generation BTK inhibitors in mantle cell lymphoma (MCL).

Quite a few next-generation inhibitors are in development, says Fenske. Two classes of BTK inhibitors exist in MCL: covalent inhibitors and noncovalent inhibitors. Acalabrutinib (Calquence) and ibrutinib (Imbruvica) covalently bind to the BTK enzyme and when there is a mutation where the drug resides, then it cannot bind anymore; this leads to the development of resistance,explains Fenske. A new category of BTK inhibitors are noncovalent binders that still appear to block the enzyme in vitro, even when that mutation is present.

The field can envision a day, hopefully not too far down the road, when a patient with MCL who shows resistance to ibrutinib or acalabrutinib could have a BTK mutation analysis performed and that would inform which BTK inhibitor they should be switched to, concludes Fenske.

Related Videos
Tycel Phillips, MD
Tycel Phillips, MD
Muhamad Alhaj Moustafa, MD, MS, hematologist, medical oncologist, Departments of Hematology and Oncology (Medical), Mayo Clinic
Jonathon B. Cohen, MD, MS
A panel of 6 experts on follicular lymphoma and mantle cell lymphoma seated at a long desk
William B. Pearse, MD
Jonathon B. Cohen, MD, MS, of Winship Cancer Institute
A panel of 6 experts on follicular lymphoma and mantle cell lymphoma seated at a long desk
A panel of 6 experts on follicular lymphoma and mantle cell lymphoma seated at a long desk